Semaglutide vs Wegovy: product identity, weight-management label, and online access

Wegovy is a specific FDA-approved brand product with product-specific labeling. The word semaglutide alone does not identify Wegovy, a labeled indication, a dosage form, or a pharmacy pathway. A patient-specific compounded prescription is not FDA-approved Wegovy or a generic, equivalent, or interchangeable substitute.

Wegovy is a semaglutide brand with weight-management labeling for specific patients and cardiovascular-risk labeling in certain adults. Semaglutide can also appear in Ozempic, oral semaglutide, or compounded-prescription discussions, so patients should ask which exact product and indication are being considered.

No. A compounded semaglutide prescription may be considered only when clinically and legally appropriate, but the finished compounded medication is not FDA-approved and should not be marketed as a generic Wegovy pen or an exact copy of an FDA-approved product.

The clinic may be discussing a different product or prescription pathway. A responsible clinic should state the exact finished product, whether it is FDA-approved or compounded, why it fits, how it is dispensed, what it costs, and how follow-up works before a patient pays.

Possibly, but switching should not be automatic. A prescriber should review your current product, dose timing, side effects, response, diagnosis, glucose medicines, pregnancy plans, pharmacy access, and whether the alternative is clinically and legally appropriate.

Avoid no-prescription sellers, research-use vials marketed for human use, unclear imported products, semaglutide sodium or acetate claims, hidden pharmacy sourcing, broken cold-chain shipping, guaranteed outcomes, and websites that provide dose, click-count, or conversion charts without clinician evaluation.